Acquired myopia in Vogt–Koyanagi–Harada disease

Takahashi, Hiroyuki; Takase, Hiroshi; Terada, Yukiko; Mochizuki, Manabu; Ohno‐Matsui, Kyoko

doi:10.1007/s10792-018-0841-2

Cited by 10 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 17 It was reported that eyes with significant myopic progression developed severe SGF within 4.3 ± 3.1 years, and the mean refractive error was −3.17 diopter (D) in progression of myopia in > −1.0 D and −2.89 D in no progression myopia group and no significant difference was found. 24 Additionally, no significant difference was observed in our short follow-up study, thus we think that a smaller SERE may be a risk factor leading to SGF, and that myopia progresses over a long interval.…”

Section: Discussionmentioning

confidence: 51%

Predictive Biomarker for Progression Into the Sunset Glow Fundus of Vogt-Koyanagi-Harada Disease, Using Adaptive Binarization of Fundus Photographs

Komuku

Ishikawa

Ide

et al. 2020

Trans. Vis. Sci. Tech.

View full text Add to dashboard Cite

Purpose The sunset glow fundus (SGF) appearance in Vogt-Koyanagi-Harada (VKH) disease was evaluated by means of adaptive binarization of patients’ fundus photographs. Methods Twenty-nine Japanese patients with acute VKH were enrolled in this study. We evaluated one eye of each patient, and thereby divided the patients into two groups; SGF+ and SGF− at 6 months after treatment. We compared patient age, gender, and spherical equivalent refractive error (SERE) and choroidal thickness measured using optical coherence tomography. We also compared the choroidal vascular appearance index (CVAI), derived by adaptive binarization image processing of fundus photographs, between the two groups. Measurements of choroidal thickness and CVAI were taken at the onset of disease, and 1, 3, and 6 months after treatment. The sunset glow index (SGI), as previously reported, was calculated using color fundus photographs, and compared to the CVAI. Results Eight patients (27.6%) were categorized into the SGF+ group. At all time points, the mean CVAI in the SGF+ group was significantly greater than that in the SGF− group. No significant difference was observed in choroidal thicknesses at any time point. The SGI was significantly greater in the SGF+ group at 6 months. Conclusions CVAI could be a new predictive biomarker for the development of SGF in patients with VKH disease. Translational Relevance Detecting SGF is important for management of patients with VKH, and CVAI may indicate the possibility of developing into SGF, although the color fundus photographs do not yet show SGF at that time.

show abstract

Section: Discussionmentioning

confidence: 51%

Predictive Biomarker for Progression Into the Sunset Glow Fundus of Vogt-Koyanagi-Harada Disease, Using Adaptive Binarization of Fundus Photographs

Komuku

Ishikawa

Ide

et al. 2020

Trans. Vis. Sci. Tech.

View full text Add to dashboard Cite

show abstract

“…87 However, patients with an acquired choroidal thinning still demonstrate axial elongation without developing posterior staphylomas. 88 Furthermore, patients with retinitis pigmentosa can develop posterior staphylomas in areas where the choroid was intact. 89 Bruch's membrane is an acellular, five-layered extracellular matrix located between the RPE and choroid.…”

Section: Animal Models Of Posterior Staphyloma Poste-mentioning

confidence: 99%

IMI Pathologic Myopia

Ohno‐Matsui

Yamashiro

et al. 2021

Invest. Ophthalmol. Vis. Sci.

Self Cite

160

159

View full text Add to dashboard Cite

Pathologic myopia is a major cause of visual impairment worldwide. Pathologic myopia is distinctly different from high myopia. High myopia is a high degree of myopic refractive error, whereas pathologic myopia is defined by a presence of typical complications in the fundus (posterior staphyloma or myopic maculopathy equal to or more serious than diffuse choroidal atrophy). Pathologic myopia often occurs in eyes with high myopia, however its complications especially posterior staphyloma can also occur in eyes without high myopia. Owing to a recent advance in ocular imaging, an objective and accurate diagnosis of pathologic myopia has become possible. Especially, optical coherence tomography has revealed novel lesions like dome-shaped macula and myopic traction maculopathy. Wide-field optical coherence tomography has succeeded in visualizing the entire extent of large staphylomas. The effectiveness of new therapies for complications have been shown, such as anti-VEGF therapies for myopic macular neovascularization and vitreoretinal surgery for myopic traction maculopathy. Myopia, especially childhood myopia, has been increasing rapidly in the world. In parallel with an increase in myopia, the prevalence of high myopia has also been increasing. However, it remains unclear whether or not pathologic myopia will increase in parallel with an increase of myopia itself. In addition, it has remained unclear whether genes responsible for pathologic myopia are the same as those for myopia in general, or whether pathologic myopia is genetically different from other myopia.

show abstract

“…Takahashi et al reported that in Vogt-Koyanagi-Harada (VKH) disease, progression of myopia occurs with increasing axial length. In addition, the sunset glow fundus was more frequently observed in VKH patients with myopia progression than in patients without myopia progression, and the subfoveal choroidal thickness was found to be thinner ( 33 ). We investigated the inhibitory effect of lactoferrin on myopia onset and progression using a mouse model of lens-induced myopia.…”

Section: Inflammation and Myopiamentioning

confidence: 99%

Multiple Factors Causing Myopia and the Possible Treatments: A Mini Review

Shinojima

Negishi

Tsubota³

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

The myopia epidemic has become a global public health problem. Although myopia is progressing worldwide, the recent coronavirus infections 2019 (COVID-19) outbreak has spurred myopia progression. The current evidence-based treatments for humans are atropine eye drops, optical treatment with defocus, use of orthokeratology, extending proximity working distance, pausing from near work every half hour and increased time outside the home. Studies on myopia using animal models have been conducted for more than 40 years. In recent years, new mechanisms of myopia suppression have been revealed from animal experiments such as inflammation control, intraocular pressure control, light control, and the activity of early growth response protein 1 control. This mini-review provides a summary of the scientific evidence currently available on the control of myopia, and the possible treatments mitigating myopia.

show abstract

Acquired myopia in Vogt–Koyanagi–Harada disease

Abstract: Myopia progression as well as increase in axial length occurs in VKH disease. The link between choroidal thinning and axial length elongation in VKH patients gives some insights into axial length increase of pathologic myopia.

Cited by 10 publications

References 19 publications

Predictive Biomarker for Progression Into the Sunset Glow Fundus of Vogt-Koyanagi-Harada Disease, Using Adaptive Binarization of Fundus Photographs

Predictive Biomarker for Progression Into the Sunset Glow Fundus of Vogt-Koyanagi-Harada Disease, Using Adaptive Binarization of Fundus Photographs

IMI Pathologic Myopia

Multiple Factors Causing Myopia and the Possible Treatments: A Mini Review

Contact Info

Product

Resources

About